|
|
|
|
|
|
|
M T W Thu F |
|
10 September, 2026 |
|
|
sponsored by
|
|
|
|
Stop Searching Through COAs and Batch Records. Start Asking Them Questions.
|
| Katalyze digitizes COAs, paper batch records, and PDFs, then creates an ontology tailored to your operation and builds a knowledge graph connecting those records with relevant system data. Your teams can search that knowledge and ask questions in plain language, with every answer traceable to its original source. Built for GxP environments, Katalyze puts fragmented records to work across Yield Optimization, Deviation Investigation, and Raw Material Characterization, with your experts in control. |
|
|
|
|
|
|
|
|
|
|
|
|
|
CAR-Ts have been generating a lot of excitement in oncology. But recently disclosed trial deaths have raised questions about their use in autoimmune disease. In an interview with Merck, I asked why it doesn't have any CAR-Ts in its core pipeline. Oncology clinical development head Marjorie Green cited logistical issues and the challenges of scaling the personalized therapies for patients. (In contrast, the production of its Moderna-partnered personalized cancer vaccine is an “easier process,” she said.) |
|
|
|
Nicole DeFeudis |
Senior Reporter, Endpoints News
@Nicole_DeFeudis
|
|
|
|
|
|
|
by Nicole DeFeudis
|
FDA regulators said they’re open to “innovative approaches” for studying the effects of psychedelic therapies, including the use of comparators other than placebo. The comments... | |
|
|
|
|
|
|
|
|
|
|
by Max Gelman
|
The FDA has placed a troubled Biohaven program on partial clinical hold, the company disclosed Wednesday. An epilepsy study of the experimental drug called BHV-7000... | |
|
|
|
|
|
|
by Anna Brown
|
The UK government's move to pay more for medicines and foster a closer relationship with drugmakers appears to have led to an increase in the... | |
|
|
|
|
|
|
by Kyle LaHucik
|
We'll be unveiling this year's Endpoints 11 in Boston on the night of Sept. 24. Join us. The biopharma industry feels much different than... | |
|
|
|
 |
|
|
|
by ENDPOINTS |
Plus news about Tevard Biosciences, Disc Medicine, InduPro, EMD Serono and Frazier Life Sciences. Shionogi fails mid-stage stroke trial: The company’s experimental drug redasemtide didn’t... | |
|
|
|
